ATE493657T1 - Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs - Google Patents

Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs

Info

Publication number
ATE493657T1
ATE493657T1 AT04798043T AT04798043T ATE493657T1 AT E493657 T1 ATE493657 T1 AT E493657T1 AT 04798043 T AT04798043 T AT 04798043T AT 04798043 T AT04798043 T AT 04798043T AT E493657 T1 ATE493657 T1 AT E493657T1
Authority
AT
Austria
Prior art keywords
molecules
angiogenesis
jam
inhibiting
cancer
Prior art date
Application number
AT04798043T
Other languages
English (en)
Inventor
Beat Imhof
Michel Aurrand-Lions
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,123 external-priority patent/US7642341B2/en
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE493657T1 publication Critical patent/ATE493657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04798043T 2003-11-19 2004-11-19 Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs ATE493657T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03026629A EP1533617A1 (de) 2003-11-19 2003-11-19 Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
US10/738,123 US7642341B2 (en) 2003-12-18 2003-12-18 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
PCT/EP2004/013247 WO2005050213A1 (en) 2003-11-19 2004-11-19 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Publications (1)

Publication Number Publication Date
ATE493657T1 true ATE493657T1 (de) 2011-01-15

Family

ID=34621557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798043T ATE493657T1 (de) 2003-11-19 2004-11-19 Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs

Country Status (18)

Country Link
US (1) US7790863B2 (de)
EP (2) EP1533617A1 (de)
JP (1) JP2007515159A (de)
KR (1) KR101135834B1 (de)
CN (1) CN1890567B (de)
AT (1) ATE493657T1 (de)
AU (1) AU2004291989B2 (de)
BR (1) BRPI0415541B8 (de)
CA (1) CA2546406C (de)
DE (1) DE602004030819D1 (de)
EA (1) EA009037B1 (de)
ES (1) ES2358905T3 (de)
IL (1) IL175686A (de)
MX (1) MXPA06005523A (de)
NO (1) NO20062793L (de)
SG (1) SG148190A1 (de)
WO (1) WO2005050213A1 (de)
ZA (1) ZA200603069B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836329B2 (ja) * 1999-03-11 2011-12-14 メルク セローノ エス．エイ． 血管接着分子およびその機能の調節
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
CA2663243A1 (en) * 2006-09-28 2008-04-03 Merck Serono S.A. Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
EP2626435B1 (de) 2008-03-21 2016-06-01 MDxHealth S.A. Erkennung und Prognose von Gebärmutterhalskrebs
US8962274B2 (en) 2009-02-27 2015-02-24 Novartis Ag Methods for selecting eukaryotic cells expressing a heterologous protein
EP2670772B1 (de) 2011-02-02 2016-07-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Antagonisten von grasp55 zur verwendung als ein medikament
WO2012160031A1 (en) * 2011-05-24 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for prognosing solid tumor outcome
WO2014066590A1 (en) * 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
GB201415367D0 (en) * 2014-08-29 2014-10-15 Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K Methods for detecting abnormalities in haemoglobin
EP3277841A1 (de) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuer biomarker des ergebnisses bei aml
RU2599545C1 (ru) * 2015-11-06 2016-10-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ подавления роста опухоли основе in vitro репрограммирования макрофагов на м1 фенотип с повышенной способностью к продукции оксида азота в эксперименте

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
JP4836329B2 (ja) * 1999-03-11 2011-12-14 メルク セローノ エス．エイ． 血管接着分子およびその機能の調節
EP1212422B1 (de) 1999-08-24 2007-02-21 Medarex, Inc. Humane antikörper gegen ctla-4 und deren verwendungen
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
WO2003008541A2 (en) * 2001-07-16 2003-01-30 Eli Lilly And Company Extracellular junctional adhesion molecules
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
IL162835A0 (en) 2002-01-09 2005-11-20 Medarex Inc Human monoclonal antibodies against cd30
NZ541050A (en) * 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
MXPA06005523A (es) 2006-12-14
ZA200603069B (en) 2007-09-26
HK1097908A1 (en) 2007-07-06
BRPI0415541B8 (pt) 2021-05-25
US7790863B2 (en) 2010-09-07
CA2546406A1 (en) 2005-06-02
BRPI0415541A (pt) 2006-12-26
KR20060130562A (ko) 2006-12-19
DE602004030819D1 (de) 2011-02-10
EA200600995A1 (ru) 2006-10-27
EP1685405B1 (de) 2010-12-29
IL175686A0 (en) 2006-09-05
BRPI0415541B1 (pt) 2018-11-27
KR101135834B1 (ko) 2012-04-16
US20070202110A1 (en) 2007-08-30
EP1533617A1 (de) 2005-05-25
AU2004291989A1 (en) 2005-06-02
CA2546406C (en) 2013-04-09
CN1890567B (zh) 2012-12-12
EP1685405A1 (de) 2006-08-02
SG148190A1 (en) 2008-12-31
ES2358905T3 (es) 2011-05-16
WO2005050213A1 (en) 2005-06-02
NO20062793L (no) 2006-08-18
AU2004291989B2 (en) 2009-08-06
EA009037B1 (ru) 2007-10-26
CN1890567A (zh) 2007-01-03
IL175686A (en) 2012-02-29
JP2007515159A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
ATE493657T1 (de) Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
EP2620450A3 (de) Antikörperzusammensetzungen gegen CTL4
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
WO2005095457A3 (en) Immunoglobulins
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2010021697A3 (en) Antibodies to ccr2
MX2009002522A (es) Antagonistas de wnt y su uso en el diagnóstico y tratamiento de trastornos mediados por wnt.
DE59706863D1 (de) Perfluoralkylhaltige metallkomplexe und ihre verwendung in der nmr-diagnostik
WO2008045406A3 (en) COMPOUNDS, SCREENINGS, AND METHODS OF TREATMENT
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
ATE480641T1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
WO2004098391A3 (en) Methods for detecting parvovirous infections
ATE547431T1 (de) Single-chain-antikörper gegen den 37 kda/67 kda lamininrezeptor als werkzeuge zur diagnose und therapie von prionerkrankungen und krebs, deren herstellung und verwendung
WO2002000939A3 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2004087759A3 (en) Method and compositions for conversion of antibody activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties